Activation of TRPV1 and TRPC4 was found to be detrimental to psoriasis, whereas TRPA1 was found beneficial in preclinical studies.340 Lee et al.341 reported that the inhibition of TRPV1 activity, which activates ALX/FPR2 receptors, coupled with the control over CGRP release, significantly alleviated psoriasis-like pruritus and inflammation in an imiquimod (IMQ) animal model of psoriasis. Here, TRPV1 is linked to psoriasis.